Meptid 100 mg/ml Solution for Injection

  • Name:

    Meptid 100 mg/ml Solution for Injection

  • Company:
    info
  • Active Ingredients:

    Meptazinol hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/01/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 21/1/2020

Click on this link to Download PDF directly

Almirall Limited

Large-ALM_AW_LOGO_MV_Positive_CMYK_1579525802

Company Products

Medicine NameActive Ingredients
Medicine Name Almogran 12.5 mg Film-coated tablet Active Ingredients Almotriptan D, L-hydrogen malate
Medicine Name Meptid 100 mg/ml Solution for Injection Active Ingredients Meptazinol hydrochloride
Medicine Name Meptid 200 mg Film-Coated Tablets Active Ingredients Meptazinol hydrochloride
Medicine Name Skilarence 30 mg gastro-resistant tablets Active Ingredients Dimethyl fumarate
Medicine Name Skilarence 30 mg, 120 mg gastro-resisistant tablets Active Ingredients Dimethyl fumarate
Medicine Name Solaraze 3% Gel Active Ingredients Diclofenac Sodium
Medicine Name Vaniqa 11.5% cream Active Ingredients Eflornithine hydrochloride monohydrate
1 - 0 of 7 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 21 January 2020 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Date of revision: July 2019

Updated on 21 January 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Reordering of Adverse Effects as per SmPC.

Updated on 21 January 2020 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Date of revision July 2019

Updated on 21 January 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Reorder of side effects as per SmPC

Updated on 20 January 2020 PIL

Reasons for updating

  • Improved presentation of PIL

Free text change information supplied by the pharmaceutical company

Change of Almirall Logo on printed artwork.

Updated on 22 September 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 22 September 2017 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 31 March 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 4.8 Addition of QRD ADR reporting statement.

Updated on 31 March 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 26 March 2015 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 17 March 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • section 4.3 updated to strengthen the safety statements already under sections 4.4 and 4.5 namely contraindicating use during an asthma attacks and for patients on MAOIs and for 14 days after stopping MAOIs

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

·         section 2 updated in line with QRD
·         section 3 for the injection updated to align with the description parameter as detailed in the finished product specification

  • section 4.3 updated to strengthen the safety statements already under sections 4.4 and 4.5 namely contraindicating use during an asthma attacks and for patients on MAOIs and for 14 days after stopping MAOIs
·        section 4.4 updated by deleting the cautionary statement regarding MAOIs as this is now under section 4.3
·        section 4.5 updated with minor rewording
·        section 4.8 updated by ranking undesirable events under headings of frequency using the following convention: very common (≥ 1/10); common (≥1/100 to ≤1/10); uncommon (≥1/1,000 to ≤1/100); rare (≥1/10,000 to ≤1/1,000); very rare (≤1/10,000); not known (cannot be estimated from the available data).  This was purely a formatting request by the IMB; where within section 4.8, it was written that these were the "most commonly reported adverse reactions", these AEs were slotted under the tabular heading very common and those detailed as uncommon were slotted under the uncommon tabular heading under the relevant system organ class; "occassional reports" were re-classified as very rare reports.  
·        section 4.9 updated with minor rewording
section 7 updated with change of name of MAH from "Laboratorios Almirall SA" to Almirall SA

Updated on 11 March 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to name of manufacturer

Updated on 30 June 2009 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 18 June 2009 PIL

Reasons for updating

  • New PIL for new product